-
1.发明授权公开(公告)号：US07981421B2
公开(公告)日：2011-07-19
申请号：US12686659
申请日：2010-01-13
申请人： Tong Zhou , Kimihisa Ichikawa , Robert P. Kimberly , William J. Koopman , Jun Ohsumi , Albert F. LoBuglio , Donald J. Buchsbaum
发明人： Tong Zhou , Kimihisa Ichikawa , Robert P. Kimberly , William J. Koopman , Jun Ohsumi , Albert F. LoBuglio , Donald J. Buchsbaum
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/39541 , A61K41/00 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 详细描述了任选与各种治疗剂组合的抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
公开(公告)号：US07279160B2
公开(公告)日：2007-10-09
申请号：US10281479
申请日：2002-10-25
申请人： Tong Zhou , Kimihisa Ichikawa , Robert P. Kimberly , William J. Koopman , Jun Ohsumi , Albert F. Lobuglio , Donald J. Buchsbaum
发明人： Tong Zhou , Kimihisa Ichikawa , Robert P. Kimberly , William J. Koopman , Jun Ohsumi , Albert F. Lobuglio , Donald J. Buchsbaum
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/39541 , A61K41/00 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 详细描述了任选与各种治疗剂组合的抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
3.发明申请公开(公告)号：US20110002887A1
公开(公告)日：2011-01-06
申请号：US12686659
申请日：2010-01-13
申请人： Robert P. Kimberly , William J. Koopman , Albert F. LoBuglio , Tong Zhou , Donald J. Buchsbaum , Kimihisa Ichikawa , Jun Ohsumi
发明人： Robert P. Kimberly , William J. Koopman , Albert F. LoBuglio , Tong Zhou , Donald J. Buchsbaum , Kimihisa Ichikawa , Jun Ohsumi
IPC分类号： A61K38/21 , A61K38/19 , A61K39/395 , C12N5/071 , A61P29/00 , A61P35/00 , A61P37/02 , C12N13/00
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/39541 , A61K41/00 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 详细描述了任选与各种治疗剂组合的抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
4.发明授权公开(公告)号：US07704502B2
公开(公告)日：2010-04-27
申请号：US11752153
申请日：2007-05-22
申请人： Tong Zhou , Kimihisa Ichikawa , Robert P. Kimberly , William J. Koopman , Jun Ohsumi , Albert F. LoBuglio , Donald J. Buchsbaum
发明人： Tong Zhou , Kimihisa Ichikawa , Robert P. Kimberly , William J. Koopman , Jun Ohsumi , Albert F. LoBuglio , Donald J. Buchsbaum
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/39541 , A61K41/00 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 详细描述了任选与各种治疗剂组合的抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
5.发明申请Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents 有权针对肿瘤坏死因子相关凋亡诱导配体受体和其他治疗剂的选择性抗体的组合公开(公告)号：US20090022707A1
公开(公告)日：2009-01-22
申请号：US11752153
申请日：2007-05-22
申请人： Robert P. Kimberly , William J. Koopman , Albert F. LoBuglio , Tong Zhou , Donald J. Buchsbaum , Kimihisa Ichikawa , Jun Oshumi
发明人： Robert P. Kimberly , William J. Koopman , Albert F. LoBuglio , Tong Zhou , Donald J. Buchsbaum , Kimihisa Ichikawa , Jun Oshumi
IPC分类号： A61K39/395 , A61P29/00 , A61P31/00
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/39541 , A61K41/00 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 详细描述了任选与各种治疗剂组合的抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
公开(公告)号：US20090208483A1
公开(公告)日：2009-08-20
申请号：US12187818
申请日：2008-08-07
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28 , C12N5/02 , C12N13/00
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/395 , A61K41/00 , A61K45/06 , A61K2039/505 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了DR5和DR4抗体的核酸序列和氨基酸序列，并且已经产生了含有并表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
公开(公告)号：US07476383B2
公开(公告)日：2009-01-13
申请号：US10286132
申请日：2002-10-31
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/395 , A61K41/00 , A61K45/06 , A61K2039/505 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了DR5和DR4抗体的核酸序列和氨基酸序列，并且已经产生了含有并表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
8.发明申请ANTIBODY SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USES THEREOF 有权肿瘤坏死因子相关药物诱导配体受体的抗体选择及其用途公开(公告)号：US20120076792A1
公开(公告)日：2012-03-29
申请号：US13269811
申请日：2011-10-10
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of o the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体的下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
9.发明授权Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof 有权抗肿瘤坏死因子相关凋亡诱导配体受体的选择性抗体及其用途公开(公告)号：US08329180B2
公开(公告)日：2012-12-11
申请号：US13269811
申请日：2011-10-10
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
10.发明申请Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof 有权抗体选择性肿瘤坏死因子相关凋亡诱导配体受体及其用途公开(公告)号：US20130243780A1
公开(公告)日：2013-09-19
申请号：US13621383
申请日：2012-09-17
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.05 秒)
